These results are consistent with the recent finding that administration of exogenous LEAP2 to men without obesity (to achieve mildly supraphysiological plasma LEAP2 concentrations) reduced food intake at an ad libitum test lunch, although no decreases in appetite ratings were seen [13]. Here, LEAP2 is linked to obesity due to melanocortin 4 receptor deficiency.